Skip to main content

Advertisement

SpringerLink
Log in

Neurologic complications of antitumor antibody therapies

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Antibody-based therapy is being explored across a variety of disease types. Several successes in oncology have become part of standard care for diseases such as colorectal cancer and non-Hodgkin’s lymphoma. Traditional chemotherapeutic agents have had significant dose-limiting neurologic toxicities associated with their use. Although there are rare incidences of significant neurologic complications of antibody cancer therapy, these treatments are generally very well tolerated. Because most antibody therapy is adjunctive to other treatments, attribution to the immunologic component is often difficult to discern.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435–445.

    PubMed  CAS  Google Scholar 

  2. Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177–186.

    Article  PubMed  CAS  Google Scholar 

  3. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  4. Emmanouilides C, Sfakiotaki G, Androulakis N, et al.: Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007, 7:91.

    Article  PubMed  CAS  Google Scholar 

  5. Kerr C: Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol 2005, 6:266.

    Article  PubMed  Google Scholar 

  6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23:3502–3508.

    Article  PubMed  CAS  Google Scholar 

  7. Nguyen TD, Abrey LE: Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol 2007, 5:375–376; discussion 377–379.

    PubMed  Google Scholar 

  8. Scappaticci FA, Skillings JR, Holden SN, et al.: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232–1239.

    Article  PubMed  Google Scholar 

  9. Hambleton J, Skillings J, Kabbinavar F, et al.: Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC) [abstract]. Am Soc Clin Oncol 2005, 23:3554.

    Google Scholar 

  10. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253–1259.

    Article  PubMed  CAS  Google Scholar 

  11. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722–4729.

    Article  PubMed  CAS  Google Scholar 

  12. Avastin shows encouraging results in phase II study in patients with the most aggressive form of brain cancer [news release]. South San Francisco, CA: Genentech; November 18, 2007.

  13. Tam CS, Galanos J, Seymour JF, et al.: Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004, 77:72–76.

    Article  PubMed  CAS  Google Scholar 

  14. Norman JK, Parke JT, Wilson DA, McNall-Knapp RY: Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2007, 49:198–203.

    Article  PubMed  Google Scholar 

  15. Allen JA, Adlakha A, Bergethon PR: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006, 63:1475–1478.

    Article  PubMed  Google Scholar 

  16. Glusker P, Recht L, Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab [letter]. N Engl J Med 2006, 354:980–982; discussion 982.

    Article  PubMed  CAS  Google Scholar 

  17. Ozcan C, Wong SJ, Hari P: Reversible posterior leukoencephalopathy syndrome and bevacizumab [letter]. N Engl J Med 2006, 354:980–982; discussion 982.

    Article  PubMed  Google Scholar 

  18. Cobleigh MA, Langmuir VK, Sledge GW, et al.: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30:117–124.

    Article  PubMed  CAS  Google Scholar 

  19. Haefner MD, Siciliano RD, Widmer LA, et al.: Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie 2007, 30:138–140.

    Article  PubMed  Google Scholar 

  20. Goldberg SL, Pecora AL, Alter RS, et al.: Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002, 99:1486–1488.

    Article  PubMed  CAS  Google Scholar 

  21. Freim Wahl SG, Folvik MR, Torp SH: Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 2007, 26:68–73.

    PubMed  CAS  Google Scholar 

  22. Kranick SM, Mowry EM, Rosenfeld MR: Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 2007, 69:704–706.

    Article  PubMed  Google Scholar 

  23. Pelosini M, Focosi D, Rita F, et al.: Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 2007 Dec 7 (Epub ahead of print).

  24. Rituxan warning. FDA Consumer 2007, 41:3.

  25. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417–1423.

    Article  PubMed  CAS  Google Scholar 

  26. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567–578.

    Article  PubMed  CAS  Google Scholar 

  27. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040–2048.

    Article  PubMed  CAS  Google Scholar 

  28. ERBITUX (Cetuximab) package insert. ImClone Systems Incorporated, New York, NY, and Bristol-Myers Squibb Company, Princeton, NJ: May 2007.

  29. Van Cutsem E, Siena S, Humblet Y, et al.: An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008, 19:92–98.

    Article  PubMed  Google Scholar 

  30. Patel SJ, Shapiro WR, Laske DW, et al.: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005, 56:1243–1252; discussion 1252–1253.

    Article  PubMed  Google Scholar 

  31. Reardon DA, Akabani G, Coleman RE, et al.: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006, 24:115–122.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuro-Oncology Branch, National Cancer Institute, 9030 Old Georgetown Road, Bloch Building 82, Room 243, Bethesda, MD, 20892, USA

    Teri N. Kreisl

Authors
  1. Teri N. Kreisl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teri N. Kreisl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kreisl, T.N. Neurologic complications of antitumor antibody therapies. Curr Neurol Neurosci Rep 8, 259–263 (2008). https://doi.org/10.1007/s11910-008-0039-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-008-0039-5

Keywords

Search

Navigation